ABT Stock Analysis — Abbott Laboratories
Sector: Healthcare
AI Verdict
Abbott trades cheap for the growth you're getting, but the market is demanding proof that its diversified moat can actually deliver the rebound analysts expect.
Competitive Moat
Abbott Laboratories commands a defensible moat through its diversified portfolio of diagnostics, medical devices, and branded nutrition products, which are embedded in hospital systems and consumer health routines worldwide. Its global distribution network and regulatory expertise create high switching costs for hospitals and insurers.
Summary
A sharp drop in share price (-28.25% over the past year) has reset expectations just as analysts forecast a major earnings rebound.
Where It Stands
Abbott trades at 15.7x next year's earnings—well below the healthcare sector median of 22x—while its RSI of 63.7 signals the stock is approaching elevated territory after a rough -28.25% year.
Key Metrics
- RSI: 63.7 — Near Overbought
- Trailing P/E: 26.6x
- Forward P/E: 15.7x
- PEG Ratio: 0.38
- Earnings Growth: +0.7%
- Revenue Growth: +0.1%
- Market Cap: $166.7B
- Dividend Yield: 0.03%
- 1-Year Return: -28.25%
- 52-Week High: $137.49
- 52-Week Low: $81.97
Analyst Consensus
25 Buy · 10 Hold · 0 Sell (35 analysts)
Bull Case
With forward EPS growth expected at 69.5% and a forward P/E of 15.7x, you're getting a rare combination of low price and high growth for a $166.7B healthcare giant.
Bear Case
If the forward P/E multiple reverts even halfway to the sector median (from 15.7x up to 19x), it would require the full 69.5% EPS growth just to keep the stock flat, so any miss could trigger another sharp pullback, especially with RSI at 63.7.
Catalyst to Watch
Watch for quarterly earnings—if the company delivers on the 69.5% EPS growth forecast, the valuation gap could close quickly.